0 0 0 0 0.0033440514469454 0.0418006430868167 0.022508038585209 0.0488424437299035
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron Reports Third Quarter 2019 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: PR Newswire
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ --Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter 2018 Dupixent® global net sales(5), which increased 141% to $633 million versus third quarter 2018, drove higher profitability from antibody collaboration with Sanofi Third quarter 2019 GAAP diluted EPS was $5.86 and third quarter non-GAAP diluted EPS(1) was $6.67 Company announces $1.0 billion share repurchase programRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2019 and provided a business update."Regeneron delivered positive financial and operational results this quarter, marked by significant EYLEA and Dupixent sales growth and progress across our pipeline," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We are broadening our efforts in retinal and type 2 inflam [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron Reports Third Quarter 2019 Financial and Operating Results

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: PR Newswire
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ --Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter 2018 Dupixent® global net sales(5), which increased 141% to $633 million versus third quarter 2018, drove higher profitability from antibody collaboration with Sanofi Third quarter 2019 GAAP diluted EPS was $5.86 and third quarter non-GAAP diluted EPS(1) was $6.67 Company announces $1.0 billion share repurchase programRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2019 and provided a business update."Regeneron delivered positive financial and operational results this quarter, marked by significant EYLEA and Dupixent sales growth and progress across our pipeline," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We are broadening our efforts in retinal and type 2 inflam [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS